Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
Condition(s) studied
Study summary
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.
It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.
Eligibility
Primary outcome measure(s)
- Detectable serum neural autoantibodies — at baseline
such as NMDAR、AMPAR1、AMPAR2、LGI1、lg LON5、DPPX、GAD65、mGluR5、MOG - Neuronal surface antibodies-mediated autoimmune- encephalitis — at baseline
diagnosed according to the 2016 diagnostic criteria
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Hangzhou | Zhejiang | Recruiting |
More Shen Chun-Hong trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06388161 on ClinicalTrials.gov ↗ ← All trials in China